Quick Answer
Valion Bio, Inc. reported Gross Profit of $2.0 thousand for fiscal year 2024.
Valion Bio, Inc. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2024 | $2.0K | -99.3% |
| 2023 | $287.0K | -4.0% |
| 2022 | $299.0K | +886.8% |
| 2021 | -$38.0K | — |
Quarterly Gross Profit
| Quarter Ending | Gross Profit | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$145.0K | -429.5% | -368.5% |
| June 30, 2025 | $54.0K | +80.0% | +8.0% |
| March 31, 2025 | $50.0K | -70.1% | +13.6% |
| September 30, 2024 | $44.0K | -59.3% | +46.7% |
| June 30, 2024 | $30.0K | -50.8% | -82.0% |
| March 31, 2024 | $167.0K | +47.8% | +54.6% |
| September 30, 2023 | $108.0K | +71.4% | +77.0% |
| June 30, 2023 | $61.0K | -51.2% | -46.0% |
- Valion Bio, Inc. showed a decrease of -99.3% in Gross Profit compared to the prior fiscal year.
- Over the 2021–2024 period, Valion Bio, Inc.’s gross profit has grown by 105.3% (from -$38.0 thousand to $2.0 thousand).
- The most recent figure is from Valion Bio, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 21, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: